SEC Form 4 · accession 0000891293-15-000036
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Sep 21, 2015
Accepted (ET)
Sep 23, 2015 · 6:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 21, 2015 | A | 151,739 | $0.00 | A | 800,953 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As disclosed by CTIC in a Form 8-K filed on 1/31/14, CTIC granted a bonus opportunity to the reporting person that is payable in shares of CTIC common stock upon the achievement of certain performance goals. This transaction reflects the issuance of common stock by CTIC pursuant to the award in connection with CTIC's determination that the Pacritinib Phase III goal under the award has been satisfied.